

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 October 2003 (30.10.2003)


PCT

(10) International Publication Number
WO 03/089409 A1

- (51) International Patent Classification: C07D 207/26, 207/38, 401/12, 211/88, 211/76, A61K 31/4015, 31/4025, A61P 25/00, 25/22, 25/24
- (21) International Application Number: PCT/EP03/04180
- (22) International Filing Date: 17 April 2003 (17.04.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0209029.8 19 April 2002 (19.04.2002) GB
0220781.9 6 September 2002 (06.09.2002) GB
- (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DAMIANI, FedERICA [IT/IT]; GlaxoSmithKline S.p.A, Via Alessandro Fleming 2, I-37135 Verona (IT). HAMPRECHT, Dieter [DE/IT]; GlaxoSmithKline S.p.A, Via Alessandro Fleming 2, I-37135 Verona (IT). JAXA-CHAMIEC, Albert, Andrzej [GB/IT]; GlaxoSmithKline S.p.A, Via Alessandro Fleming 2, I-37135 Verona (IT). MICHELI, Fabrizio [IT/IT]; GlaxoSmithKline S.p.A, Via Alessandro Fleming 2, I-37135 Verona (IT). PASQUARELLO, Alessandra [IT/IT]; GlaxoSmithKline S.p.A, Via Alessandro Fleming 2, I-37135 Verona (IT). TEDESCO, Giovanna [IT/IT]; GlaxoSmithKline S.p.A, Via Alessandro Fleming 2, I-37135 Verona (IT).
- (74) Agent: KONDO, Rie; GlaxoSmithKline, 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report

[Continued on next page]

(54) Title: COMPOUNDS HAVING AFFINITY AT 5HT_{2C} RECEPTOR AND USE THEREOF IN THERAPY



(57) Abstract: Compounds of formula (I) or a pharmaceutically acceptable salt thereof are disclosed: wherein R_1 is hydrogen, hydroxy, fluoro, chloro, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, C_{1-6} alkoxy or halo C_{1-6} alkoxy; m is 0 when --- is a double bond and m is 1 when --- is a single bond; R_2 is hydrogen, halogen, cyano, nitro, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, halo C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, C_{1-6} alkylthio, amino, mono- or di- C_{1-6} alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is $-(CH_2-CH_2)-$, $-(CH=CH)-$, $-(CH_2)_3-$, $-C(CH_3)_2-$, $-(CH=CH-CH_2)-$, $-(CH_2-CH=CH)-$ or a group $-(CHR_3)-$ wherein R_3 is hydrogen, halogen, hydroxy, cyano, nitro, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, halo C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy or C_{1-6} alkylthio; R_3 is halogen, cyano, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, C_{1-6} alkoxy, C_{1-6} alkylthio, hydroxy, amino, mono- or di- C_{1-6} alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, halo C_{1-6} alkyl, halo C_{1-6} alkoxy, aryl, aryl C_{1-6} alkyl, aryl C_{1-6} alkyloxy, aryl C_{1-6} alkylthio or $COOR_6$, $CONR_7R_8$ or COR_9 wherein R_6 , R_7 , R_8 and R_9 are independently hydrogen or C_{1-6} alkyl; p is 0, 1 or 2 or 3; R_4 is hydrogen, halogen, hydroxy, cyano, nitro, C_{1-6} alkyl, C_{1-6} alkanoyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyloxy, halo C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, C_{1-6} alkylthio, amino, mono- or di- C_{1-6} alkylamino or an N-linked 4 to 7 membered heterocyclic group; Y is oxygen, sulfur, $-CH_2-$ or NR_{10} wherein R_{10} is hydrogen or C_{1-6} alkyl; D is a single bond, $-CH_2-$, $-(CH_2)_2-$ or $-CH=CH-$; and Z is an optionally substituted C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, an optionally substituted N-linked 4 to 7 membered heterocyclic group, or Z is $-NR_{11}R_{12}$ where R_{11} and R_{12} are independently hydrogen or C_{1-6} alkyl. Methods of preparation and uses thereof in therapy, particularly for CNS disorders such as depression and anxiety, are also disclosed.

WO 03/089409 A1